علاج الإيدز عندما لا يمكن تناول العلاج المضاد للفيروسات القهقرية الفموي بشكل منتظم

References

DOI: 10.1001/jama.2024.24543

Injectable long-acting cabotegravir plus long-acting rilpivirine in conjunction with intensive case management and adherence support may be considered for people with viremia who meet the criteria below when no other treatment options are effective (AIIa under the conditions described):

— Unable to take oral ART consistently despite extensive efforts and clinical support

— High risk of HIV disease progression (CD4+ cell count <200/μL or history of AIDS-defining complications)

— A virus susceptible to both cabotegravir and rilpivirine

Some clinical programs have reported success in caring for such individuals using injectable long-acting cabotegravir plus long-acting rilpivirine every 4 weeks initially (and subsequently every 8 weeks), in conjunction with intensive case management services, as a way to achieve and maintain virologic control.

For those unable to take oral ART with advanced HIV disease, long-acting cabotegravir plus long-acting rilpivirine in conjunction with intensive case management and adherence support may be considered for people with viremia who meet the criteria below when no other treatment options are effective (evidence rating: AIIa under the conditions described).